A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 38/28 (2006.01) A61K 9/14 (2006.01) C07K 14/62 (2006.01) A61K 38/00 (2006.01)
Patent
CA 2216516
The present invention discloses various parenteral pharmaceutical formulations having a protracted effect, which comprise: a sterile aqueous suspension of about 20 U/mL to about 500 U/mL insulin analog, about 5 mg/mL to about 10 mg/mL sodium chloride, about 0.2 to about 2.0 mg/mL physiologically acceptable buffer, a zinc ion content of about 0.07 mg/mL to about 0.1 mg/mL, and a physiologically acceptable preservative at a pH of about 6.5 to about 7.8; such that less than 5 % of the analog present in the suspension is in the dissolved state.
Formulations pharmaceutiques diverses à administration parentérale ayant un effet prolongé, comprenant: une suspension aqueuse stérile d'environ 20 U/mL à 500 mg/mL d'analogue de l'insuline, d'environ 5 mg/mL à 10 mg/mL de chlorure de sodium, d'environ 0,2 à 2,0 mg/mL d'un tampon physiologiquement acceptable, une teneur en ions zinc d'environ 0,07 mg/mL à 0,1 mg/mL, et un conservateur physiologiquement acceptable d'un pH d'environ 6,5 à 7,8; dans des conditions telles que moins de 5 % de l'analogue présent dans la suspension soit à l'état dissous.
de Felippis Michael Rosario
Frank Bruce Hill
Eli Lilly And Company
Gowling Lafleur Henderson Llp
LandOfFree
Monomeric insulin analog formulations does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monomeric insulin analog formulations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monomeric insulin analog formulations will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1809958